stockportfolio.pro
Stocks / HRMY vs PGNY
HRMY vs PGNY
Harmony Biosciences Holdings, Inc. and Progyny, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Harmony Biosciences Holdings, Inc. (HRMY) | Progyny, Inc. (PGNY) | |
|---|---|---|
| Market cap | $2.1B | $2.0B |
| Revenue (latest FY) | $868.45M | $1.29B |
| Net income (latest FY) | $158.69M | $58.52M |
| Revenue growth (5y CAGR) | 40.3% | 30.2% |
| Net margin | 18.3% | 4.5% |
| Return on equity | 18.2% | 11.3% |
| P/E ratio | 14.3 | 33.5 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 5 | 7 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open HRMY — free Open PGNY — freeFrequently asked questions
Which is bigger, HRMY or PGNY?
Harmony Biosciences Holdings, Inc. is larger by market capitalization — $2.1B versus $2.0B.
Which grows faster, HRMY or PGNY?
Over the last five fiscal years, Harmony Biosciences Holdings, Inc. grew revenue faster — 40.3%/yr versus 30.2%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.